Integration of Magic Tag(R) technology to Biophage biosensor platform
extends diagnostic capabilities
MONTREAL, March 13 /CNW Telbec/ - (TSX-V: BUG). Biophage Pharma Inc.
(Biophage) and a2sp Limited (a2sp), a privately held UK biotech company
(Warwick, England) announced today the signing of a collaborative agreement
aimed at combining a2sp's Magic Tag(R) immobilization technology with the
Biophage biosensor platform. Magic Tag(R) uses linkers, which are activated by
daylight, for the immobilization of biomolecules (including phages) onto
different surfaces such as magnetic beads, biosensors and micro-array
Biophage and a2sp also announced that they have jointly filed a patent
application on February 16, 2007 relating to "methods for immobilizing viruses
(phages) using photo-reactive linkers".
The integration of Magic Tag(R) linkers with our biosensor platforms will
result in a major enhancement of the diagnostic capabilities of Biophage
biosensor technologies, the speed of immobilizing phages to different surfaces
and the reduction of problems associated with non-specific binding (minimizing
false results). Unlike other existing technologies that employ UV-light
activated linkers, the new, specially designed Magic Tag(R) linkers are
activated by daylight thereby avoiding the use of UV-light which could
breakdown phages and proteins.
"With the integration of Magic Tag(R) immobilization technology, Biophage
marks a new and very exciting development in our portfolio of products,
extending the range of diseases we will now be able to diagnose to include
viral infections, etc.", said Dr. Mandeville, President and Chief Executive
Officer of Biophage Pharma Inc. "The use of linkers is a ground breaking
innovation in our detection platforms and is a major step forward in the
development and commercialization of robust, reliable and rapid biosensors for
the detection of a large number of diseases." concluded Dr. Mandeville.
"We are delighted to be working with Biophage Pharma combining our
expertise in immobilization chemistry with Biophage's leading position in the
use of phages. This collaboration further broadens the application of both
technologies and intellectual property estate", said Dr Suzanne Dilly,
Director of a2sp Limited.
About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian
biotechnology company focused on the development of innovative phage-based
products and technologies for the detection and management of bacterial
contaminations. Founded in 1995, Biophage operates three divisions: (1) The
phage therapy division for the management of bacterial contaminations in the
medical, veterinary and environment fields; (2) The Biosensors division for
the development and commercialization of Biosensors, more particularly a
compact PDS96(R) biosensor which is entering in the pre-commercialization
stage; (3) The Immunotox Labs division, which provides services in
Immunogenicity and Immunotoxicity, Nanotoxicity and Ecotoxicology, Beryllium
sensitivity testing and MELISA(R) testing for the detection of sensitization
to more than 200 different allergens including metals, penicillin, gluten and
About a2sp Limited
a2sp Limited is a privately held UK biotechnology company providing
Chemical Genomics Services for drug discovery. The core technology upon which
the company was founded is licensed as Magic Tag(R) immobilization platform.
This technology has a broad range of applications in chemical genomics, drug
discovery, drug screening and to the immobilization of bio-molecules,
measurement and characterization of small- and macro-molecules. Established in
2006, a2sp Limited is developing a portfolio of therapeutic programs based on
the use of Magic Tag(R) technology to identify drug re-profiling
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Biophage Pharma Inc.: Rosemonde Mandeville,
M.B., Ch.B., PhD, President and Chief Executive Officer, (514) 496-1488,
firstname.lastname@example.org; a2sp Limited: Paul Taylor, PhD
Director and Chief Scientific Officer, +44 (0)24 7652 4375,
email@example.com; Renmark Financial Communications Inc.: Christine
Stewart: firstname.lastname@example.org; Maurice Dagenais:
email@example.com, (514) 939-3989, Fax: (514) 939-3717,